Olga Grishina

1.7k total citations
16 papers, 269 citations indexed

About

Olga Grishina is a scholar working on Hematology, Molecular Biology and Public Health, Environmental and Occupational Health. According to data from OpenAlex, Olga Grishina has authored 16 papers receiving a total of 269 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 5 papers in Molecular Biology and 4 papers in Public Health, Environmental and Occupational Health. Recurrent topics in Olga Grishina's work include Hematopoietic Stem Cell Transplantation (6 papers), Acute Myeloid Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (4 papers). Olga Grishina is often cited by papers focused on Hematopoietic Stem Cell Transplantation (6 papers), Acute Myeloid Leukemia Research (5 papers) and Acute Lymphoblastic Leukemia research (4 papers). Olga Grishina collaborates with scholars based in Germany, Switzerland and Finland. Olga Grishina's co-authors include Jürgen Finke, Claudia Schmoor, Hartmut Bertz, Gabriele Ihorst, Gèrard Socié, Liisa Volin, Matthias Stelljes, Wolfgang Bethge, Hellmut Ottinger and Dominik Heim and has published in prestigious journals such as Blood, BMC Cancer and Bone Marrow Transplantation.

In The Last Decade

Olga Grishina

14 papers receiving 267 citations

Peers

Countries citing papers authored by Olga Grishina

Since Specialization

Citations

This map shows the geographic impact of Olga Grishina's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Olga Grishina with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Olga Grishina more than expected).

Fields of papers citing papers by Olga Grishina

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Olga Grishina. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Olga Grishina. The network helps show where Olga Grishina may publish in the future.

Co-authorship network of co-authors of Olga Grishina

This figure shows the co-authorship network connecting the top 25 collaborators of Olga Grishina. A scholar is included among the top collaborators of Olga Grishina based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Olga Grishina. Olga Grishina is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	Safety and tolerability of losartan to treat recessive dystrophic epidermolysis bullosa in children (REFLECT): an open-label, single-arm, phase 1/2 trial 2024 ·EClinicalMedicine ·Dimitra Kiritsi, Franziska Schauer, (unknown), (unknown), (unknown), Agnes Schwieger‐Briel, Hagen Ott, Claudia Schmoor, Olga Grishina, Dédée F. Murrell, Brigitte Stiller, Tobias Zahn, Alexander Nyström, (unknown)	3
2	Continued decitabine/all-trans retinoic acid treatment: extended complete remission in an elderly AML patient with multi-hit TP53 lesions and complex-monosomal karyotype 2024 ·Clinical Epigenetics ·(unknown), (unknown), (unknown), Olga Grishina, Dietmar Pfeifer, (unknown), Konstanze Döhner, Christoph Plass, Heiko Becker, Claudia Schmoor, Maike de Wit, Michael Lübbert	1
3	Long-term decitabine/retinoic acid maintenance treatment in an elderly sAML patient with high-risk genetics 2023 ·Clinical Epigenetics ·(unknown), Olga Grishina, (unknown), Milena Pantić, Dietmar Pfeifer, Claudia Schmoor, (unknown), Justus Duyster, Heiko Becker, Michael Lübbert	2
4	Thiotepa–fludarabine–treosulfan conditioning for 2nd allogeneic HCT from an alternative unrelated donor for patients with AML: a prospective multicenter phase II trial 2022 ·Bone Marrow Transplantation ·Jürgen Finke, Claudia Schmoor, Matthias Stelljes, Andreas Burchert, Peter Dreger, Ute Hegenbart, (unknown), Martin Bornhäuser, Kristina Sohlbach, Natalie Schub, Christian Reicherts, (unknown), Bertram Glaß, Hartmut Bertz, Olga Grishina	2
5	Phase I Study of the LSD1 Inhibitor Tranylcypromine (TCP) in Combination with All-Trans Retinoic Acid (ATRA) and Low-Dose Cytarabine (LDAC) in Elderly, Medically Non-Fit Patients with AML or High-Risk MDS (TRANSATRA trial) 2022 ·Blood ·Michael Lübbert, Claudia Schmoor, Tobias Berg, (unknown), Marcus M. Schittenhelm, Katharina S. Götze, Caroline Pabst, Andrea Kündgen, (unknown), (unknown), (unknown), (unknown), Johannes Jung, (unknown), Manfred Jung, Roland Schüle, Ralph Wäsch, Olga Grishina	8
6	Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628) 2018 ·BMC Cancer ·Nikolas von Bubnoff, Gabriele Ihorst, Olga Grishina, Nadine Röthling, Hartmut Bertz, Justus Duyster, Jürgen Finke, Robert Zeiser	42
7	Long-term outcomes after standard graft-versus-host disease prophylaxis with or without anti-human-T-lymphocyte immunoglobulin in haemopoietic cell transplantation from matched unrelated donors: final results of a randomised controlled trial 2017 ·The Lancet Haematology ·Jürgen Finke, Claudia Schmoor, Wolfgang Bethge, Hellmut Ottinger, Matthias Stelljes, Liisa Volin, Dominik Heim, Hartmut Bertz, Olga Grishina, Gèrard Socié	66
8	A Randomized Controlled Study of the Efficacy of Pregabalin in the Treatment of Opiate Withdrawal Syndrome 2017 ·Neuroscience and Behavioral Physiology ·(unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Olga Grishina, (unknown), Marina Vetrova, Н. Г. Незнанов	1
9	A randomized single blind study of the efficacy of pregabalin in the treatment of opioid withdrawal syndrome 2016 ·S S Korsakov Journal of Neurology and Psychiatry ·Evgeny Krupitsky, (unknown), (unknown), (unknown), (unknown), (unknown), Olga Grishina, (unknown), Marina Vetrova, Н. Г. Незнанов	10
10	High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma—a randomized phase III trial (MATRix) 2016 ·BMC Cancer ·Elisabeth Schorb, Jürgen Finke, Andrés J.M. Ferreri, Gabriele Ihorst, (unknown), Benjamin Kasenda, Kristina Fritsch, Heidi Fricker, Elvira Burger, Olga Grishina, Elke Valk, Emanuele Zucca, Gerald Illerhaus	43
11	DECIDER: prospective randomized multicenter phase II trial of low-dose decitabine (DAC) administered alone or in combination with the histone deacetylase inhibitor valproic acid (VPA) and all-trans retinoic acid (ATRA) in patients >60 years with acute myeloid leukemia who are ineligible for induction chemotherapy 2015 ·BMC Cancer ·Olga Grishina, Claudia Schmoor, Konstanze Döhner, Björn Hackanson, Beate Lubrich, Annette M. May, (unknown), Michael J. Müller, Michael Lübbert	42
12	Results of an Open, Non-Comparative, Phase I/II Investigator Initiated Trial (IIT) in Relapsed or Refractory Multiple Myeloma Patients Using Vorinostat, Bortezomib, Doxorubicin and Dexamethasone (VBDD) 2015 ·Blood ·Alexander Keller, Johannes M. Waldschmidt, Dagmar Wider, (unknown), (unknown), Heike Reinhardt, Milena Pantić, Olga Grishina, Gabriele Ihorst, Annette M. May, (unknown), (unknown), Justus Duyster, Manfred Jung, Monika Engelhardt, Ralph Wäsch	1
13	Vorinostat (V), bortezomib (B), doxorubicin (Dox) and dexamethasone (Dex, VBDD) in relapsed or refractory multiple myeloma patients (pts): results of an open, non-comparative, phase I/II investigator initiated trial (IIT) 2015 ·Clinical Lymphoma Myeloma & Leukemia ·Alexander Keller, Johannes M. Waldschmidt, Dagmar Wider, (unknown), Marco Möller, Heike Reinhardt, Milena Pantić, Olga Grishina, Gabriele Ihorst, Annette M. May, (unknown), (unknown), Manfred Jung, Justus Duyster, Ralph Wäsch, Monika Engelhardt	0
14	Randomized Trial on GvHD Prophylaxis with or without Anti-Human T-Lymphocyte Immunoglobulin ATG-Fresenius (ATG-F) in Allogeneic Hematopoietic Cell Transplantation from Matched Unrelated Donors: Final Long-Term Results after 8.6 Years Median Follow-up 2015 ·Blood ·Jürgen Finke, Claudia Schmoor, Wolfgang Bethge, Hellmut Ottinger, Matthias Stelljes, Liisa Volin, Dominik Heim, Hartmut Bertz, Olga Grishina, Gèrard Socié	2
15	Prognostic Factors Affecting Outcome after Allogeneic Transplantation for Hematological Malignancies from Unrelated Donors: Results from a Randomized Trial 2012 ·Biology of Blood and Marrow Transplantation ·Jürgen Finke, Claudia Schmoor, Wolfgang Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, Liisa Volin, Dominik Heim, Rainer Schwerdtfeger, Karin Kolbe, Jiřı́ Mayer, Johan Maertens, Werner Linkesch, Ernst Holler, Vladimír Koza, Martin Bornhäuser, Hermann Einsele, Hartmut Bertz, Olga Grishina, Gèrard Socié	46
16	Randomized Trial on GvHD Prophylaxis with or without Anti-T-Cell Globulin ATG-Fresenius (ATG-F) In Allogeneic Hematopoietic Cell Transplantation From Matched Unrelated Donors: Final Results and Analysis of Prognostic Factors 2010 ·Blood ·Jürgen Finke, Claudia Schmoor, Wolfgang Bethge, Hellmut Ottinger, Matthias Stelljes, Axel R. Zander, Liisa Volin, Dominik Heim, Rainer Schwerdtfeger, Hartmut Bertz, Olga Grishina, Gérard Socié	0

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact